Search
Search Results
-
Long-term, continuous infusion of single-agent dinutuximab beta for relapsed/refractory neuroblastoma: an open-label, single-arm, Phase 2 study
BackgroundShort-term infusions of dinutuximab beta plus isotretinoin and cytokines administered in previous immunotherapy studies in neuroblastoma...
-
Phase 1 study of high-dose DFMO, celecoxib, cyclophosphamide and topotecan for patients with relapsed neuroblastoma: a New Approaches to Neuroblastoma Therapy trial
BackgroundMYC genes regulate ornithine decarboxylase (Odc) to increase intratumoral polyamines. We conducted a Phase I trial [NCT02030964] to...
-
Genomic ALK alterations in primary and relapsed neuroblastoma
BackgroundGenomic alterations of the anaplastic lymphoma kinase gene ( ALK ) occur recurrently in neuroblastoma, a pediatric malignancy of the...
-
Lorlatinib with or without chemotherapy in ALK-driven refractory/relapsed neuroblastoma: phase 1 trial results
Neuroblastomas harbor ALK aberrations clinically resistant to crizotinib yet sensitive pre-clinically to the third-generation ALK inhibitor...
-
Anti-GD2 CAR-NKT cells in relapsed or refractory neuroblastoma: updated phase 1 trial interim results
Vα24-invariant natural killer T cells (NKTs) have anti-tumor properties that can be enhanced by chimeric antigen receptors (CARs). Here we report...
-
Increased MCL1 dependency leads to new applications of BH3-mimetics in drug-resistant neuroblastoma
BackgroundNeuroblastoma is a paediatric cancer that is characterised by poor prognosis for chemoresistant disease, highlighting the need for better...
-
Immunotherapy of Neuroblastoma Targeting GD2 and Beyond
Neuroblastoma is the most common extracranial solid tumor in children. Although low-risk neuroblastoma is mostly curable, the outcome of high-risk...
-
Molecular-guided therapy for the treatment of patients with relapsed and refractory childhood cancers: a Beat Childhood Cancer Research Consortium trial
BackgroundChildren with relapsed central nervous system (CNS tumors), neuroblastoma, sarcomas, and other rare solid tumors face poor outcomes. This...
-
Immunotherapy Options for Neuroblastoma: What is on the Horizon?
Purpose of ReviewNeuroblastoma is the most commonly seen extracranial tumor in children originating from the sympathetic nervous system. It is...
-
Available Preclinical Tools for Neuroblastoma
Neuroblastoma is the most predominant and deadly cancer in infants and in young children and contributes significantly to childhood cancer deaths....
-
TRAF4 Silencing Induces Cell Apoptosis and Improves Retinoic Acid Sensitivity in Human Neuroblastoma
Neuroblastoma (NB) is a pediatric malignancy that arises in the peripheral nervous system, and the prognosis in the high-risk group remains dismal,...
-
Neuroblastoma arises in early fetal development and its evolutionary duration predicts outcome
Neuroblastoma, the most frequent solid tumor in infants, shows very diverse outcomes from spontaneous regression to fatal disease. When these...
-
Feasibility of functional precision medicine for guiding treatment of relapsed or refractory pediatric cancers
Children with rare, relapsed or refractory cancers often face limited treatment options, and few predictive biomarkers are available that can enable...
-
Serum brain-derived neurotrophic factor (BDNF) as predictors of childhood neuroblastoma relapse
BackgroundNeuroblastoma (NB) is a childhood malignant tumor,50% of high-risk NB children still have recurrence, and the long-term survival rate is...
-
Targeting WEE1 kinase as a p53-independent therapeutic strategy in high-risk and relapsed acute lymphoblastic leukemia
BackgroundOutcomes for patients with relapsed acute lymphoblastic leukemia (ALL) are poor and there is a need for novel therapies to improve...
-
Identification of a novel eighteen-gene signature of recurrent metastasis neuroblastoma
AbstractNeuroblastoma is the most common malignant tumor in childhood, and metastases occur in more than 30% patients. Recurrent metastasis is the...
-
Available Preclinical Tools for Neuroblastoma
Neuroblastoma is the most predominant and deadly cancer in infants and in young children and contributes significantly to childhood cancer deaths....
-
Promising Molecular Targets and Novel Therapeutic Approaches in Neuroblastoma
Purpose of ReviewThis article provides a brief and up-to-date overview of promising molecular targets and novel therapeutic approaches in...
-
Clonal evolution during metastatic spread in high-risk neuroblastoma
Patients with high-risk neuroblastoma generally present with widely metastatic disease and often relapse despite intensive therapy. As most studies...
-
Rottlerin and genistein inhibit neuroblastoma cell proliferation and invasion through EF2K suppression and related protein pathways
Neuroblastoma is one of the most common solid tumors in children younger than 1 year of age, with poor prognosis and survival rates. Therefore, novel...
